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Blood transfusion at regular intervals to 
maintain hemoglobin above 10 gm/d l  
along with daily chelation therapy remains 
to be the main therapeutic management in 
thalassemia. ~ These thalassemic children 
are at higher isk of developing transfusion 
transmitted infections, which include 
hepatitis B, C, D, HIV, cytomegalovirus, 
malaria, syphilis etc. Blood banks in this 
country are unable to screen the donors for 
all types of transfusion transmitted infec- 
tions due to cost prohibition, lack of orga- 
nization, awareness and many other tech- 
nical factors. Thus, in the prevailing cir- 
cumstances of inadequate donor screening 
strategy in this country, information on the 
dynamics of hepatotropic viral infection 
amongst multitransfused individuals as- 
sumes an importance to devise a rational 
long term approach in the management of 
such indixffduals. With the advent of sero- 
logical markers of various hepatotropic vi- 
ral infection, it is possible at present to as- 
sess the magnitude, natural course and 
therapeutic response of such patients. 
The present review deals with serologi- 
cal changes in hepatitis B, C and D, along 
with the prevalence, the natural course 
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and the current management in 
multitransfused thalassemics. 
Hepatitis "B' Virus Serology 
Hepatitis B virus (HBV) is a medium size 
DNA virus and its infection in humans 
manifests as acute or chronic hepatitis. Its 
transmission is mainly through parenteral 
route. Acute hepatitis B virus infection is 
often self-limiting and only 10% of the pa- 
tients, subsequent to acute HBV infection, 
develop chronic sequelae like chronic 
hepatitis and cirrhosis" Serological profile 
subsequent to acute and chronic hepatitis 
B infection is shown in Figs. 1 and 2. Hepa- 
titis B surface antigen (HBsAg) from HBV 
envelop is detected in serum both during 
acute and chronic hepatitis.' Presence of 
HBsAg is indicative of active HBV infec- 
tion. However, its presence or titer neither 
suggests acute or chronic HBV infection 
nor the severity (mild or severe) of hepati- 
tis. Some patients may even have HBsAg 
in high concentrations and are perfectly 
healthy and are termed as carriers of 
HBV 3 HBeAg is secreted from nucleocap- 
sid gene of HBV. 4 It is found during acute 
and chronic hepatitis and is not detected in 
the serum in the absence of HBsAg. Pres- 
ence of HBsAg along with HBsAg is sug- 
gestive of viral replication and active liver 
disease. HBcAg (Hepatitis B core antigen) 
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Fig. 1. Serology in acute hepatitis B virus infec- 
tion. 
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Fig. 2. Serology m chronic hepatitis Bvirus in- 
fection. 
is not detectable by conventional ELISA/ 
RIA techniques. However, it can be de- 
tected in the liver by immunohistochemis- 
try and serves as a sensitive mean for de- 
tecting ongoing viral replication2 ,6 HBV 
DNA is also detectable in serum during 
acute and chronic HBV infection. 5,6 It can 
be detected by using direct "blot' or liquid 
hybridization assays. Recently PCR tech- 
nique has been used for detecting HBV 
DNA in the serum and serves as th.e most 
sensitive method, as the HBV DNA in level 
of 10 pg/ml can be detected easily. 7HBV 
DNA can be detected practically in all the 
patients who are positive for HBsAg and 
even before HBsAg appears or after it dis- 
appears. Detection of HBV DNA by "blot" 
technique is of the same clinical signifi- 
cance as that of the detection of HBsAg 
and HBeAg which is currently used to as- 
sess the outcome of treatment with antivi- 
ral agents. ~
Anti-HBs develops after the disappear- 
ance of HBsAg and during convalescence 
from hepatitis. It presence is indicative of 
recover), and immunity against HBV infec- 
tion2 Successful vaccination also induces 
anti-HBs but the level of protection is vari- 
able. It is of interest that some chronic 
HBsAg carriers have both HBsAg and anti- 
HBs which is possible only when the anti- 
bodies are directed against HBsAg 
epitopes and not shared by the circulating 
antigen2 ~Anti-HBs these people are not 
protective. 
IgM anti-HBc is detected at the onset of 
acute hepatitis and persists for 3 to 12 
months if the acute hepatitis resolves." 
However, if the patient develops chronic 
hepatitis B, the Igm anti-HBc may persist 
as long as viral replication persists. ~z Igm 
anti-HBc appears with the onset of symp- 
toms and rise in transaminases level. Its 
presence is suggestive of previous or ongo- 
ing infection with HBV as its level persists 
for long periods. 13 It serves as a good tool 
for the epidemiological studies to deter- 
mine the prevalence of present or past 
HBV infection. IgG anti-HBc does not ap- 
pear following HBV vaccination. Anti-HBe 
becomes detectable when HBeAg disap- 
pears during acute or chronic hepatitis B. 
Appearance of anti-HBe indicates the reso- 
lution of underlying infection, except when 
a precore HBV mutant is causing hepatitis. 
1995; Vol. 62. No. 6 THE INDIAN JOURNAL OF PEDIATRICS 657 
Hepatitis C Virus Serology 
Hepatitis C virus (HCV) is a RNA virus 
identified in 1989 and is responsible for 
majority of transfusion transmitted non-A 
and non-B hepatitis.U,15 Serological tests for 
HCV areavailable but are still in the pro- 
cess .of deve.lopment. Presently only anti- 
HCV is commercially available. ~6 Initially 
anti-HCV recombinant yeast polypetide (C 
100-3) derived from a non-structural re- 
gion of HCVgenome was used. As the an- 
tigen was against a small HCV genome, 
there was high false positivity. No, several 
recombinant proteins from various regions 
of HCV genome have been developed for 
testing anti-HCV. Use of these antigens 
have increased the specificity and sensitiv- 
ity of the test. These Und/UIrd generation 
anti-HCV assays do :not distinguish be- 
tween Igm and IgG antibodies. Anti-HCV 
is detected late during the course of acute 
hepatitis (between 4 to 24 weeks) and it 
disappears over years. While in chronic 
hepatitis C, anti-HCV persists indefinitely 
(Fig. 3). HCV RNA can only be detected by 
PCR technique as the virus circulates in 
very low l~vels: Majority of" the patients 
with acute hepatitis C, 40 to 75% of the pa- 
tients with chronic hepatitis C have viral 
genome in'the serumY J8 
Hepatitis D Virus Serology 
Hepatitis delta virus (HDV) is a small 
RNA virus that causes hepatitis in those 
who are carriers of HBV (superinfection) 
or can be translrtitted simultaneously 
along with HBV (coinfection). Both forms 
of HDV infection should be considered 
separately because of the differences in the 
prognosis and the serological changes 
(Figs. 4 & 5). Igm anti-HDV appears earlier 
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Fig. 3. Hepatitis "D" virus & Hepatitis B virus 
coinfection. 
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Fig. 4. Hepatitis D virus super infection. 
during the course of HDV infection and is 
more reliable as a single diagnostic test for 
infection with HDV. Igm anti-HDV contin- 
ues to i~ersist in patients with chronic delta 
hepatitis while in acute resolving infection 
its levels disappear over few months. Anti- 
HDV appears late during HDV infection 
and infrequently anti-HDV may not be de- 
tectable, majority of the patients with co- 
infection (HDV & HBV) clear HBV and 
HDV whereas the patients with superin- 
fection develop chronic rapidly progres- 
sive delta hepatifisY 
HDV antigen tests have been developed 
which are presently being used for re- 
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search and are not applicable for clinical 
use. '8 HDV RNA is being detected by mo- 
lecular hybridization or by PCR and is 
used for monitoring therapy. Diagnosis of 
HDV can be established in the presence of 
clinical features of acute hepatitis and posi- 
tivity of HBsAg & anti-HDV in the serum. 
Coinfection can be diagnosed when the se- 
rum is positive for Igm anti-HBC along 
with anti-HDV. HDV infection should be 
considered as superinfection when serum 
is positive for HBsAg anti-HDV and is 
negative for Igm anti-HBc. Chronic HDV 
can be diagnosed with clinical features of 
chronic hepatitis and persistence ofHBsAg 
and anti-HDV in high titers in serum for 6 
months or more. Diagnosis of HDV infec- 
tion can be confirmed by the presence of 
HDV RNA in the serum or liver. '9 
Prevalence of Hepatitis J3, C and D 
amongst Multitransfused Thalassemics 
Majority of thalassemic children in this 
country despite repeated transfusion have 
not been investigated for the presence of 
all identificable hepatotropic viral mark- 
ers. Seven different serological patterns 
were observed in India while evaluating 
the prevalence of hepatitis B. 2~ Administra- 
tion of hepatitis B vaccination i these chil- 
dren without assessing their pre-vaccina- 
tion HBV exposure status may complicate 
the matter further if all the serological tests 
for HBV are not performed. Vaccinated 
child ten will develop anti-HBs but will not 
develop anti-HBC. Despite these limita- 
tions, the available data suggest the preva- 
lence of hepatitis B, C & D is quite high 
amongst the thalassemic children (Table 1 
& 2). Prevalence of HBsAg in thalassemic 
children is infrequent in the developed 
countries (0-9.6%) in contrast o similar 
prevalence amongst the thalassemics in In- 
dia (7.5 to 59.6%). Such a low prevalence or 
HBsAg in the developed nations has been 
achieved by stringent screening of donors 
using sensitive techniques and administra- 
t-ion of hepatitis B vaccine at the time of di- 
agnosis of thalassemia. In India, the reason 
for such as high prevalence of HBV infec- 
tion amongst the multitransfused 
thalassemic presumably is due to three ob- 
vious factors viz; (i) lack of awareness of 
HBV infection and its consequences 
amongst he thalassemics and Pediatri- 
cians; (ii) administration of HBV vaccine is 
not a routine at the time of diagnosis of 
thalassemia because of poor availability 
and (iii! high cost and unsatisfactory donor 
screening despite the recommendations of 
the government on the implementation f 
above recommendations will not only pre- 
vent HBV but also prevent HDV infection 
amongst these children. 
Prevalence of hepatitis C infection has 
been increasing over the last several years 
and its prevalence amongst the multi- 
transfused individuals is much higher in 
our country than the one reported from the 
developed countries (Table 1 & 2). In the 
absence of hepatitis C vaccine the routine 
screening of all the donors is the sole op- 
tion to contain the spread of HCV infec- 
tion. Anti-HCV posihvity amongst the 
thalassemic children in Delhi city has been 
reported to vary from 32 to 62.2%. 37 Both 
HBV and HCV are established agents to 
cause cirrhosis of liver and hepatocellular 
cancer over a period of 15 to 20 years. Un- 
less infection of such agents amongst he 
thalassemics is contained, they are likely to 
succumb from progressive irreversible 
liver damage during their adulthood, thus 
defying the basic aim of treating them with 
multiple transfusions. 
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T~E 1. Prevalence of Hepatitis B, C, D in Mult itransfused indian Thalassemic Chidren 
659 
Positivy in Percentage 
Study Place NO HBsAg Ant i -  Anti-  Others Over- Anti- Anti. 
HBsAg HBc All HCV HDV 
Mittal Delhi 27 14.8 48.1 51.8 29.6 74.1 - - 
et al-8821 
Kapil Delhi 50 10.0 40.0 62.0 - 80.0 - - 
D-89 ;2 
Bhattacharya Calcutta 70 . . . . .  14.3 - 
et aI-92 '~ 
Chandigarh 100 6.0 73.0 49.0 - 76 17.5 16.7 Gulati* 
et al-922a 
Amarapukar  Bombay 40 45 . . . .  7.0 3 
et aI-92'* 
William Delhi 54 7.4 - 9 - 66.6% 11.1 - 
et al-9225 
Jolly Lucknow 251 15.1 - I, . . . . .  
et ai-9226 
Chopra & Popli 9527 Delhi 37 59.6 - - 21.6 - 62.2 - 
Manglani Bombay 25 8.0 84.0 - 88.0 - - - 
et al-9425 
Choudhry Delhi 102 35.2 29.4 1.0 - 65.7 30.3 - 
et a-95 ~ 
*Anti HBsAg positivity of 44% was observed in donor's blood. 
TABrE 2. P reva lence  o f  Hepat i t i s  B & C in  Tha lassemia  Ma jor  in  the  Deve loped  Count r ies  
Pos i t i v i ty  in  P recentage  
Authors  Count ry  n HBsAg Ant i -HBs  Ant i -  Overa l l  Ant i -  
+ Ant i -HBc  HBC Preva lance  HCV 
Wonke  , U .K .  73 0 27.04 - 27.4 23.2 
et a1-1990 ~
de Monta lem Be lg ium 15 0.0 73.3 26.7 - 13.3 
bert  et  al F rance  172 5.9 76.2 23.3 - 25 
199231 I ta ly 118 1.2 57.6 49.2 - 50 
Cacopardo  I ta ly 152 8 55 - - 47 
et al 199232 
Dent ico I ta ly 114 9.6 29.8 9.1 47.4 -- 
et  al 199233 
Rest i  I ta ly 78 . . . .  83.3 
et al 1992 ~ 
a lFawaz  L & S. Arab ia  20 0 26.7 0 26.7 70.0 
Ramia  1993 ~ 
Lau Ch ina  99 . . . . .  34.4 
et al 19933~ 
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Evidence for Child to Child Transmission 
There are evidences that hepatitis may be 
transmitted from child to child. Franks & 
his colleagues ~ have reported that 55% of 
31 children born to HBsAg positive carrier 
had evidence of HBV infection, whereas 
0.6 ~ of 226 children born to HBsAg nega- 
tive mothers had evidence of HBV infec- 
tion. In this study authors had shown that 
in nearly half of the cases with chronic 
HBV infection in Asian children, it was 
not attributed to vertical transmission. In
another study of 429 children born to 
Hmong refugees, it was observed that 
HBV infection was detected in 30% of chil- 
dren born to mothers who were positive 
for HBsAg and 11% of children born to 
HBsAg negative mothers. 39 These observa- 
tions suggest that horizontal transmission 
of HBV from child to child occurs fre- 
quently. However, these observations 
need to be confirmed among the siblings 
of thalassemic children. William and their 
colleagues, 25 observed that 28.9% parents 
of thalassemic children had evidence of 
HBV infection. It appears most likely that 
they had acquired HBV infection from 
their children. 
Outcome of Hepatitis 
An outcome of post-transfusion hepatitis 
varies and is dependent upon multiple fac- 
tors such as age at which the exposure has 
occurred, host immunity, type of viral 
hepatitis or its mutants, hepatic iron con- 
tent of the individual, risk of repeated ex- 
posures and nature of therapy. Acute 
hepatitis B commonly has a self-limiting 
course and the infection subsides over few 
weeks. In contrast acute hepatitis.'C' fre- 
quently leads to chronicity and spontane- 
ous recovery is rare. Sufficient data on the 
natural course of hepatitis in thalassemics 
is not available. Thalassemic children have 
a high risk of developing chronic HBV in- 
fection due to three reasons : (a) multiple 
exposure to hepatitis B virus infection (b) 
compromised immune competence (c) ex- 
posure at younger age which is a known 
risk factor for chronicity. Progressive dis- 
ease due to hepatitis 'B' is believed to oc- 
cur with the persistence of viral replica- 
tion, viral mutations, transient exacerba- 
tion of viral replication or reinfection. 
Some patients lose HBeAg but continue to 
have liver disease and are positive for 
HBV DNA. 4~ In a long term follow up of 
207 HBsAg positive patients with abnor- 
mal liver function tests over 3.3 years, 27 
deaths were observed and of these 16 
(59%) died of liver failure, variceal bleed- 
ing or sepsis and 8 (30%) developed 
thepatocellular carcinoma. 
Wonke & her colleagues 3~ observed that 
the thalassemic children positive for anti- 
HCV had significantly higher plasma as- 
partate aminotransferase activity (mean 
70.3 • 10.2) and serum ferritin levels 4067 + 
2708 ng/ml) than the anti-HCV 
seronegative patients (AST 39.9 +_ 15.6 U/  
L, serum ferritin 205 + 2092 mg/ml).  
Thirty-six children underwent liver bi- 
opsy. Ten of the.twenty-one children, posi- 
tive for anti-HCV had histological evi- 
dence of chronic hepatitis or cirrhosis or 
both in contrast o 1 of 15 children who 
were seronegative for anti-HCV and had 
evidence of chronic viral hepatitis. Resti et 
a137 in a study of 78 thalassemic children 
over 13 years, observed chronic hepatitis 
in 56.7% of cases following acute HCV in- 
fection but the persistence ofanti-HCV an- 
tibodies did not correlate with the chronic 
evolution of liver disease. In contrast Lai & 
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his colleagues 43observed two episodes of 
HCV viremia in two children, due to 
reinfection with a different HCVstrain and 
reactivation of primary infection in  the 
third case. Their studies have clearly sug- 
gested the persistence and reactivation of 
HCV and even episodes of reinfection with 
different strains :of HCV in these children. 
In a large multicentric transfusion trans- 
mitted viral study, the prevalence of an 
overall NANB hepatitis was 10.9% with a 
range of 5.4 to 15.3% of cases. ~ Several 
studies have indicated that nearly 50% of 
such patients ,develop histological evi- 
dence ;( of ,! chronic ,: hepatitis.'S,48 
Asymptomatic nature of the illness associ- 
ated with fluctuation of ALT levels pre- 
vents the diagnosis o f  HCV infection. 
However, elevated levels of ALT reflect 
the ongoing viral replication. Anti-HCV 
persists in  patients who progress to 
chronic hepatitis and it may,disappear in 
those who recover clinically and biochemi- 
caUy. ~The findings of HC3/RNA by PCR in 
patients who are seronegative for ~anti- 
HCV suggest that neither normalization of 
ALT nor!disappearance of anti-HCV imply 
thel complete recovery. Ten to fifteen per- 
Jcent of the patients~make progress to cir- 
rhosis and finally to liver cancer, 7 to 18 
years after the onset of NANB hepatitis. '95~ 
Seventy percent of Japanese patients with 
HCV infection had persistence of anti- 
HCV for prolonged periods, sl Similar ob - 
servations have been made by other work- 
ers.SZ~ 
Our understanding of the natural course 
HCV infection is evolving. Factors which 
influence the rate of progression to cirrho- 
sis include the age of exposure, duration of 
infection, degree of the damage at the ini- 
tial biopsy ~ and recurrent exposures. In a 
study on post-transfusion hepatitis C, 20% 
of the patients.had cirrhosis after 10 years, 
but 66 to 71% had bridging fibrosis or cir- 
rhosis after 20 to 25 years. Nineteen per- 
cent of their cases progressed to hepatocel- 
lular carcinoma, s4Serf & his colleagues 5~ 
observed a small but significant increase in 
liver related mortality over 15 to 20 years. 
Management 
Multiple antiviral agents have been evalu- 
ated for the management of hepatitis B; & 
C (Table 3). In the initial studies adenine 
arabinoside were used but were with- 
drawn because of neuromuscular toxicity 
and limited efficacy26m Acyclovir of 6- 
dexoyacyclovir were found to be safe but 
the clinical trails revealed that they were 
not effective, s8Clinical studies with other 
antiviral agents (Zidovudine, Ganciclovir) 
and immune modifiers (levamisole, ste- 
roids, interleukin 2),have revealed that 
these agents when used alone were ineffec- 
tive or had unacceptable toxicity, s9 Among 
TABLE 3. Drugs used for Chronic Viral Hepatitis 
Antivirals 
Interferons (alfa, beta, gamma) 
Adenine Arabinoside (ara-A) 
and its derivatives 
Acyclovir / Deoxyacyclovir 
Ganciclover 
zidovudine 
Suramin 
Ouinacrine 
3-thiacytidine 
Immuno modulators 
---Corticosteroids (daily or pulses) 
--Interleukin-2 
--Thymosin. 
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the various agents evaluated for the man- 
agement of hepatitis, interferon therapy 
has been found to be the most effective, s8 
Currently the studies are in progress to 
evaluate the optimal dose and duration of 
therapy with interferons. Interferons in 
combination with other drugs are being 
tried to improve the results. Thymosin ap- 
pears to be a promising antiviral agent. It 
is a hormone like polypeptide produced by 
the thymus epithelial cells. Its mechanism 
of action is possibly by the regulation of 
maturation of T cells which in turn modu- 
lates the interferon production and stimu- 
lates the expression of interleukins. ~~ In a 
recent study Mutchnich and his col- 
leagues 61 observed that 86% of the patients 
had a sustained loss of HBV DNA after six 
months of treatment with thymosin. 
Among other agents ribavirin which is a 
synthetic nucleoside with a broad antiviral 
property appears to be a promising 
agent. 6z63 
In terferon 
With the advent of recombinant DNA 
technology three major forms of interferon 
(alfa, beta and gamma) have been made 
available. Alfa interferon is produced from 
monocytes, beta from fibroblasts and gam- 
ma from T lymphocytes. Alfa a& beta have 
more antiviral activity, bdt the majority of 
trials have employed alfa inteferon. More 
than 20 different subtypes of alfa interfer- 
on have been identified. ~ Use of recombi- 
nant interferon alfa-2b has been evaluated 
involving 162 patients in USA. 65 FDA has 
approved the use of interferon alfa-2b for 
hepatitis in 1992. 59 
Hepatitis B 
Prevalence of hepatitis B in thalassemic 
children in the developing countries has 
lowered down (Table 2) and currently 
large number of non-thalassemic patients 
with hepatitis have been treated with inter- 
feron. Unfortunately interferon trials 
amongst halassemic children with chronic 
HBV hepatitis are not available. Therefore, 
the overall results & the prognostic factors 
following interferon therapy amongst non- 
thalassemic chronic HBV infection are be- 
ing presented. 
It has been observed that 20 to 30% of 
patients with hepatitis B respond to inter- 
feron. However, in a well controlled 
multicentric study involving 169 patients, 
37% of the patients lost HBeAg & HBV 
DNA, when patients were treated with in- 
terferon in a dose of 5 million units three 
times weekly for 16 weeks, while the 
HBeAg seroconversion i  patients treated 
with daily I million units of interferon and 
untreated controls was significantly lower. 
There was also no difference in results be- 
tween the patients treated with 5 million or 
10 million units given three them weekly 
for 16 weeks. ~ serum aminotransferase 
levels returned to normal in 90% of the 
cases with a sustained loss of HBV DNA. 
Reactivation of infection was observed in 5 
to 10% of cases within one year. HBsAg be- 
came negative in 10 to 15% of cases during 
therapy of within the first three months. 
Antibodies to HBsAg appear in 75 to 90% 
of such cases. 67 Long term histological 
studies over 2 to 9 years in HBsAg nega- 
tive patients have demonstrated the ab- 
sence of disease progression along with 
improvement in the histological changes. 
Over the years, several clinical..f.eatures 
have been identified which help the clini- 
cians to predict good response to therapy. 
These factors include (a) history of acute 
hepatitis (b) short duration of the disease 
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(c) female sex (d) high levels of serum ami- 
notransferase at the onset of hepatitis (e) 
low serum levels of HBV DNA (< 100 pg/ 
ml) (f) low levels of HBeAg and (g). ab- 
sence of other medical problems involving 
other organs. 
Hepatit is C 
Large number of studies on interferon 
amongst post-transfusion chronic non-A, 
non-B hepatitis patients were initiated be- 
fore the identification of HCV in 1989. On 
retrospective s rological testing these pa- 
tients were confirmed to have HCV infec- 
tion. In one of the large trial of interferon 
amongst patients of chronic non A, non B 
hepatitis, normaliTation ofserum ALT was 
observed in 38% of those treated with 3 
Mu of interferon thrice weekly for 6 
months, 16% treated with lesser dose and 
in 4% of untreated controls. 6~ Significant 
reduction in labular and periporatal in- 
flammation was observed in treated pa- 
tients. Subsequently, 13randomized con- 
t-rolled studies on interferon have been re- 
v iewedby Davis & Lau. 69 Interferon dose 
in three studies varied between 1-10 Mu 
thrice weekly for 1-18 months. Results in 
these studies were similar. Normalization 
of ALT was seen at the end of the study in 
2.6% (range 0-6.6%) of the control group, 
27% (range 16-45%) in those treated with 1 
Mu of interferon for 6 months, in 33% 
when treated with 2 Mu for 6 months, and 
41.5% (range 35-73%)in those treated with 
3 Mu for 6 months. 69 Results of interferon 
therapy were also identical in the two Eu- 
ropean multicentric studies, 5-~,7~ In all these 
studies HCV RNA became undetectable 
with the normalization of ALT during 
therapy. 71Unfortunately majority of.pa- 
tients (50-80%), who had responded to 
treatment had relapsed within 6 months of 
cessation of interferon therapy. ~.r~ Pa- 
tients with relapse of MCV infection can be 
treated again with second course of inter- 
feron therapy. 73Pre-treatment characteris- 
tics are useful in identifying patients who 
are likely to achieve remission. Patients 
with milk histological changes and low vi- 
rus load are likely to respond, r* However, 
such patients need not be treated as the 
progression of the disease is very slow in 
these cases. 
Results of interferon therapy in small 
T~m 4. Results of Interferon Therapy in Thalassemics with Hepatitis C 
Ref. N Dose of Immediate Follow up Long term 
Interferon response period response 
(%) months (%) 
Marco 12 5 Mu/M 2 
et a1-19927s TIW x 8 wk 
Followed by 
3 Mu/M 2 77 12 55.5 
TIW x 18 wk 
Wonke 15 3 Mu/M 2 53 - - 
et a1-199376 TIW 6M 
Clemente 51 3 Mu/M 2 41 36 37 
et al 1994 TIW x 15 M. 
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number of thalassemic children with hepa- 
titis C have been tabulated in Table 4. In all 
these studies response criteria were nor- 
realization of ALT levels and loss of HCV 
RNA in the serum. An immediate response 
varied between 41 to 77 percent with long 
term response being 37 to 55.5 percent of 
cases.7~. ,'v 
In conclusion we will like to emphasiz.e 
the following facts : 
(1) Prevalence of hepatit is B virus and 
hepatitis 'C' v irus infection amongst 
multitranfused thalassemics in India is 
alarmingly high and aggressive strategies 
to control such infection are necessary to 
prevent he high morbid i ty  and mortality 
rate amongst hese chi ldren when they 
reach their youth. 
(2) Stringent donor  screening facilities, 
frequent cross checks of such screening fa- 
cilities with quality control are essential to 
decrease the prevalence of these infections. 
Public awareness about  these problem s 
through extensive media coverage along 
with the availabil ity of cheaper indig- 
enously prepared HBV vaccines is of im- 
portance for prevention of HBV infection. 
Free availability of kits for testing anti- 
HCV, alongwith the availability of trained 
personnel are not so difficult measures to 
control the phepatotropic viral infections 
which have impact on high morbidity and 
mortality. 
(3) Interferon trials either alone or in 
combination with other antiviral agents 
amongst chronic HBV & HCV infection in 
multitransfused thalassemics in this coun- 
try are required on priority to evolve a 
therapeutic policy for these children. 
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A BETTER MEASLES VACCINE 
Despite the high coverage with current vaccines, measles continues to exact a tremendous toll on 
the lives of small children. Even with global vaccine coverage running of around 78%, nearly 1.5 
million children continue to die from the disease ach year. 
At present, measles immunization in industrialized countries is given at the age of  12-15 
months, so that the early immunity acquired from the mother does not interfere with the action of 
the vaccine. Unfortunately, in developing countries where measles transmission can be very in- 
tense and the risk of infection is generally greater than in developed countries, the awning of ma- 
ternal-acquired immunity can expose children to infection long before their first birthday. WHO 
has therefore recommended that measles vaccinations in developing countries hould be adminis- 
tered at nine months. 
A measles vaccine that could be effective between the ages of ~wo and six months would be 
most valuable. It would fill the "gap" that o/ten occurs after the loss of maternal-acquired immu- 
nity, and would enable this vaccine to be include in the existing schedules of the Expanded 
programme on Immunization. 
An ideal measles vaccine should be safe, and should induce lifelong protective immunity in al- 
most 100% of recipients with a single dose administered shortly after birth. It should also be com- 
patible with other antigens dispensed at the same time, provoke mucosal immunity, interrupt wild 
measles transmission, retain its potency even at 45"C for seven days, and not be much more ex- 
pensive than the current vaccine. 
Abstracted fi'om ." 
World Health 1993; No.2, p. 24. A 
